Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
Side effects of tyrosine kinase inhibitor (TKI) treatment vary in children and adults with chronic myelogenous leukemia (CML). As children have a much longer life expectancy than adults, TKI therapy may continue for decades and with long-term consequences that differ from adults. Children may develop endocrinopathies related to "off-target" effects of TKIs, such as delayed growth, changes in bone metabolism, thyroid abnormalities, and effects on puberty and fertility. These endocrinopathies present additional challenges for pediatric patients with CML. This review critically evaluates the literature on long-term endocrine side effects of TKIs in the pediatric CML population and provides suggested recommendations.
Division of Pediatric Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.|Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Jill
J
Samis
Division of Pediatric Hematology Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Paul
P
Lee
Division of Pediatric Endocrinology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.|Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Donald
D
Zimmerman
Department of Child Health, The Ron Matricaria Institute of Molecular Medicine at Phoenix Children's Hospital, University of Arizona College of Medicine, Phoenix, Arizona.
Robert J
RJ
Arceci
Pediatric Hematology, Oncology & Stem Cell Transplantation, Department of Pediatrics, Children's Hospital, Technical University of Dresden, Dresden, Germany.
Meinolf
M
Suttorp
Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois.|Division of Pediatric Hematology Oncology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Nobuko
N
Hijiya
D000311:Adrenal Glands / Q000187:drug effects; D000814:Aniline Compounds / Q000009:adverse effects / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D016723:Bone Remodeling / Q000187:drug effects; D002648:Child; D000069439:Dasatinib / Q000009:adverse effects / Q000627:therapeutic use; D004703:Endocrine System / Q000187:drug effects* / Q000473:pathology*; D004700:Endocrine System Diseases / Q000139:chemically induced*; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D044882:Glucose Metabolism Disorders / Q000139:chemically induced; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects / Q000627:therapeutic use; D007093:Imidazoles / Q000009:adverse effects / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use*; D011724:Pyridazines / Q000009:adverse effects / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use; D011804:Quinolines / Q000009:adverse effects / Q000627:therapeutic use; D013961:Thyroid Gland / Q000187:drug effects
D000814:Aniline Compounds; D000970:Antineoplastic Agents; C581634:BCR-ABL1 fusion protein, human; D007093:Imidazoles; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; D011743:Pyrimidines; D011804:Quinolines; C545373:ponatinib; C471992:bosutinib; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl; C498826:nilotinib; D000069439:Dasatinib
CML; TKI; children; endocrine; growth